Journal article

GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia

Rohtesh S Mehta, Shernan G Holtan, Tao Wang, Michael T Hemmer, Stephen R Spellman, Mukta Arora, Daniel R Couriel, Amin M Alousi, Joseph Pidala, Hisham Abdel-Azim, Ibrahim Ahmed, Mahmoud Aljurf, Medhat Askar, Jeffery J Auletta, Vijaya Bhatt, Christopher Bredeson, Saurabh Chhabra, Shahinaz Gadalla, James Gajewski, Robert Peter Gale Show all

Blood Advances | AMER SOC HEMATOLOGY | Published : 2019

Grants

Awarded by National Institutes of Health, National Cancer Institute, National Heart, Lung, and Blood Institute


Awarded by National Institutes of Health, National Heart, Lung, and Blood Institute


Awarded by Health Resources and Services Administration/Department of Health and Human Services


Awarded by Office of Naval Research


Funding Acknowledgements

The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the National Institutes of Health, National Cancer Institute, National Heart, Lung, and Blood Institute, and National Institute of Allergy and Infectious Diseases; Grant/Cooperative Agreement 1U24HL138660 from the National Institutes of Health, National Heart, Lung, and Blood Institute and National Cancer Institute; contract HHSH250201700006C with the Health Resources and Services Administration/Department of Health and Human Services; and grants N00014-17-1-2388, N00014-171-2850, and N00014-18-1-2045 from the Office of Naval Research; and grants from Adaptive Biotechnologies; *Amgen, Inc.; anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; Atara Biotherapeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.; *Bristol-Myers Squibb Oncology; *Celgene Corporation; *Chimerix, Inc.; *CytoSen Therapeutics, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Gilead Sciences, Inc.; HistoGenetics, Inc.; Immucor; *Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Karius, Inc.; Karyopharm Therapeutics, Inc.; *Kite Pharma, Inc.; Medac, GmbH; Mediware; Medical College of Wisconsin; * Merck & Co., Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; Mundipharma EDO; National Marrow Donor Program; Novartis Pharmaceuticals Corporation; PCORI; *Pfizer, Inc; *Pharmacyclics, LLC; PIRCHE AG; *Sanofi Genzyme; *Seattle Genetics; Shire; Spectrum Pharmaceuticals, Inc.; St. Baldrick's Foundation; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; and University of Minnesota (* corporate members).